Antibodies News and Research

RSS

Aileron, Roche to expand Stapled Peptide drug collaboration

Aileron Therapeutics announced today that Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs.

16 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.

15 Nov 2011

A shot to lower 'bad' cholesterol

Patients unable to control their cholesterol levels with medications may someday be able to lower their "bad" cholesterol with a shot, according to research presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

New potential target to slow breast cancer tumor progression and metastasis

A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of researchers led by Dr. Richard Kremer from the Research Institute of the McGill University Health Centre.

11 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics, Inc. today announced initiation of a Phase 1 study of its therapeutic human antibody candidate, CDX-1127, in patients with selected malignant solid tumors or hematologic cancers.

8 Nov 2011

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

Rheumavax safe and feasible in treating RA

A vaccine designed to re-educate the immune system has been shown to be safe and feasible in the treatment of rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Study finds pregnancy safe for 80% of women with lupus

Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

7 Nov 2011

FEIBA drug safe and effective for patients with hemophilia A

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place.

3 Nov 2011

Massive clotting can destroy placenta and cause miscarriages

Researchers at St. Michael's Hospital have identified a potential new cause for unexplained miscarriages in mice.

2 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

Senior Scientific's nanomagnetic technology more sensitive in detecting breast cancer

Manhattan Scientifics announced today that "Breast Cancer Research," an international, peer-reviewed online journal, has published results of a study using Senior Scientific's nanomagnetic technology.

1 Nov 2011